Business Wire

Ricardo Commissioned to Define a Single Harmonised European Life Cycle Assessment Standard for Zero Emission Vehicles and Batteries

Share

Ricardo, a global strategic environmental and engineering consulting company, has commenced a European Union-funded project to develop a baseline for a European-wide commonly accepted and applied single life cycle assessment (LCA) approach for zero emission vehicles (ZEV) and batteries based on evidence and real-world data. This initiative is a Coordination and Support Action supported under the Horizon Europe Framework Programme and has also received funding from UK Research and Innovation (UKRI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005551/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Electric car and truck charging (Photo: Business Wire)

Currently, there is no agreed European or international standard on vehicle life cycle assessment, although there are a number of standards in draft or being developed for electric vehicle (EV) batteries. Defining a single, harmonised life cycle assessment approach for vehicles and batteries is key to providing transparency and comparability of impacts from these products. This will help to achieve Green Deal targets, making Europe the first digitally enabled circular, climate-neutral and sustainable economy. Harmonised standards will facilitate industry, mobility providers and planners to develop sustainable road transport products that are optimised to combat climate change. Ricardo is on the core team of the collaborative TranSensus LCA consortium – jointly coordinated by the Fraunhofer Institute for Structural Durability and System Reliability LBF and the Fraunhofer-Institution of Surface Engineering and Thin Films IST– which comprises 44 stakeholders from industry and research along the full value chain of zero emission vehicles and batteries including: research institutions, vehicle and battery manufacturers, the supply industry, energy providers and recyclers.

Nikolas Hill, Head of Vehicle Technologies and Fuels in Ricardo’s Sustainable Transport team said: “The major report on life cycle impacts of road vehicles that Ricardo undertook for the European Commission in 2020 highlighted the importance of life cycle assessment in sustainable product and business development, but also the challenges for its application. In particular, efforts fully to use and realise the benefits from life cycle assessment approaches by the transport sector are being hampered because there is not an official European standard for vehicle LCA. This is largely because of a lack of a consistent, fair framework or harmonised methodology, plus limitations in accessing and managing real-world data and applying consistent modelling. Through our work with our industry and research partners on this project, Ricardo policy, strategy and technology experts will help to deliver a standard, trustworthy and consistent assessment of full vehicular environmental footprints, to support organisations across the transport value chain progress their objective of achieving climate neutrality.”

Ricardo’s 2020 report for the European Commission, DG Climate Action: Determining the environmental impacts of conventionally and alternatively fuelled vehicles through LCA was the broadest and most comprehensive study of its kind to date. The report assessed the life cycle impacts of 65 different European light- and heavy-duty vehicle types and powertrain combinations. It considered the production of 60 fuel chains for conventional and alternative fuels as well as 14 different forms of electricity generation, the impacts of vehicle (and battery) manufacturing, and vehicle use and maintenance including different ‘end of life’ scenarios. The report also highlighted the positive impact of existing European Union policy in directly supporting the move to a more circular economy and the initiatives aimed at developing a sustainable value chain for hybrid and fully electric vehicles and their batteries in driving down industrial emissions and improving resource efficiency.

Ends

Notes to editors:

TranSensus LCA is funded by the European Union under the Grant Agreement #101056715. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.

About Ricardo

Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye